Investigations › GLP-1 era
Investigation No. 08 · GLP-1 era
“GLP-1 only works because it makes you eat less”
Reduced intake does most of the work on body weight. It does not account for everything the trials produced.
At a glance
- Verdict
- True but reductive
- Certainty in the evidence
- Moderate, starting at High and moved by 1 domain
- Evidence base
- SELECT randomized trial, 3.3 years · 1 study read · 17,604 people
- Last reviewed
- 11 Sept 2026
- Next review due
- Mar 2027
How people actually say it
- “It’s just an appetite suppressant with better marketing.”dismissive, and half right
- “She’s not doing anything, she just isn’t hungry.”said about somebody else, which is where this one usually lives
Why this verdict and not the next one
Reductive rather than false, because the primary mechanism really is reduced intake. What it omits is an outcome benefit and a set of weight-independent effects that change how somebody weighs the decision.
Where the claim came from
From something genuinely true. These medications reduce food intake and that route does most of the work. The reductive part is what gets dropped: a drug that only reduced intake would produce the weight loss and nothing beyond it.
What the studies did
SELECT randomized 17,604 adults aged 45 and over, all with existing cardiovascular disease and BMI above 27, none with diabetes. Over a little more than three years, heart attacks, strokes and cardiovascular deaths occurred in 6.5 percent on semaglutide against 8.0 percent on placebo. Separately, a 2025 review reports that GLP-1 receptor signalling reduces systemic and tissue inflammation in mice and humans, through mechanisms that are both weight-loss-dependent and weight-loss-independent.
Why these papers and not others
SELECT was chosen because it measured events rather than a marker, which almost nothing in this field does. The mechanistic review sits beside it and is labelled as mechanism, not outcome.
The full search and appraisal protocol, including what gets excluded and why, is set out in the method.
The evidence, study by study
| Study | Design | n | What it found | What it cannot say |
|---|---|---|---|---|
| Lincoff 2023, SELECT | Randomized outcome trial, 3.3 years | 17,604 | Cardiovascular events 6.5 percent against 8.0 percent on placebo, in adults 45+ with existing cardiovascular disease and no diabetes | Anything about a healthy thirty-year-old |
| Wong and Drucker 2025 | Review of preclinical and clinical work | — | GLP-1 receptor signalling reduces inflammation through weight-dependent and weight-independent mechanisms | Whether those mechanisms change an outcome in a person. The authors name this as open |
How the certainty grade was reached
Certainty starts at a level set by the study design, then moves down for every domain that fails a written threshold and up for every domain that clears one. The arithmetic is shown rather than asserted.
What the evidence cannot say
The review’s authors are explicit that this is an area of emerging concepts and real uncertainty. A demonstrated pathway is a reason to keep studying, not a reason for anybody to take a medication.
One person, worked through
Somebody dismisses a friend’s result as just appetite suppression. In the population SELECT enrolled, the drug did something to cardiovascular events that the weight change alone does not fully account for. That is a reason to stop calling it a diet pill, and it is not a reason for the person dismissing it to go and take one.
Whether this applies to you
A verdict is a reading of a population. Whether it describes you depends on the things below, and any one of them can change what the right move is for you.
- Existing cardiovascular disease decides how much of the outcome data describes you
- Your age since everybody in that trial was 45 or over
- Whether you have diabetes because nobody in SELECT did, and that is a separate evidence base
What would change this entry
Trials separating weight-independent effects from weight loss, in people without existing cardiovascular disease.
Read this before you act on it
This is an appraisal of published evidence, not medical or nutrition advice, and it is not a substitute for care from a clinician who knows your history, your medications and your labs. Nothing here is a diagnosis, a prescription or a treatment plan, and reading it does not create a clinician and patient relationship.
Do not start, stop or change a medication, a supplement or a diet on the strength of this page. If you are pregnant, breastfeeding, managing kidney or liver disease, diabetes, an eating disorder or any chronic condition, the general reading above may not describe you at all. Talk to your physician or a registered dietitian first.
The verdict above was true to the evidence on 11 Sept 2026. Evidence moves. Check the review date.
References
- Lincoff AM et al. N Engl J Med. 2023;389(24):2221–2232. PMID 37952131. · Wong CK, Drucker DJ. J Clin Invest. 2025;135(21). PMID 41178710.
